Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference
September 30 2019 - 4:05PM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van
Elsas, chief scientific officer of Aduro, is scheduled to present
at the 2019 Cantor Global Healthcare Conference in New York, New
York on Friday, October 4, 2019 at 8:55 am ET.
To access the live webcast and subsequent archived recording of
this and other company presentations, please visit the investor
section of Aduro's website at www.aduro.com. The archived webcast
will remain available for replay on Aduro’s website for 30
days.
About Aduro Aduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body’s natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a first-in-class humanized IgG4 monoclonal antibody that
fully blocks APRIL binding to both the BCMA and TACI receptors, is
being evaluated in IgA nephropathy. Aduro is collaborating with a
number of leading global pharmaceutical companies to help expand
and drive its product pipeline. For more information, please visit
www.aduro.com.
Contact:Noopur
Liffick510-809-2465investors@aduro.com press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024